Based on these findings, HDAC6 inhibition represents a new and promising avenue to treat PAH, avoiding the unforeseeable undesirable side effects caused by non-specific nuclear HDAC inhibitors. The gene discussed is HDAC6; the disease is pulmonary arterial hypertension.